Acadia Healthcare (ACHC)

• Market cap: $3.52B
• 1 day: -1.79%
• 5 days: -5.30%
• 1 month: -3.07%
• 3 months: -50.39%
• 6 months: -43.93%
• Year to date: -51.57%
• 1 year: -49.91%
• 5 years: 14.95%
• 10 years: -39.89%
• Sector: Healthcare
• Industry: Specialty Outpatient Facilities

About: Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.

Employees: 23,500

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

15% more call options, than puts

Call options by funds: $35.3M | Put options by funds: $30.8M

1% more funds holding

Funds holding: 302 [Q2] → 306 (+4) [Q3]

9% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 47

6% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 108

0.97% more ownership

Funds ownership: 104.84% [Q2] → 105.81% (+0.97%) [Q3]

5% less capital invested

Capital invested by funds: $6.57B [Q2] → $6.23B (-$340M) [Q3]

43% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 4 (-3) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $43 13% upside
• Avg. target: $59 54% upside
• High target: $75 98% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Deutsche Bank Pito Chickering 42% 1-year accuracy 5 / 12 met price target	98% upside $75	Buy Upgraded	12 Dec 2024
Cantor Fitzgerald Sarah James 23% 1-year accuracy 30 / 130 met price target	37% upside $52	Neutral Reiterated	10 Dec 2024
Barclays Andrew Mok 29% 1-year accuracy 18 / 62 met price target	13% upside $43	Overweight Maintained	22 Nov 2024
RBC Capital Ben Hendrix 25% 1-year accuracy 18 / 71 met price target	69% upside $64	Outperform Maintained	18 Nov 2024